115,227 Shares in Privia Health Group, Inc. (NASDAQ:PRVA) Purchased by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP purchased a new stake in Privia Health Group, Inc. (NASDAQ:PRVA) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 115,227 shares of the company’s stock, valued at approximately $2,253,000.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Privia Health Group by 1.5% in the 3rd quarter. FMR LLC now owns 18,169,043 shares of the company’s stock valued at $330,858,000 after purchasing an additional 271,645 shares during the period. Riverbridge Partners LLC raised its stake in Privia Health Group by 19.7% in the fourth quarter. Riverbridge Partners LLC now owns 5,824,458 shares of the company’s stock valued at $113,868,000 after buying an additional 958,418 shares during the period. Geode Capital Management LLC lifted its holdings in Privia Health Group by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,415,022 shares of the company’s stock valued at $43,986,000 after purchasing an additional 23,178 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Privia Health Group by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company’s stock valued at $23,092,000 after purchasing an additional 28,480 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Privia Health Group by 6.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,133,873 shares of the company’s stock worth $22,167,000 after purchasing an additional 69,649 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on PRVA shares. Piper Sandler raised their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Canaccord Genuity Group increased their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Macquarie started coverage on Privia Health Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $25.00 price target for the company. JPMorgan Chase & Co. boosted their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, November 29th. Finally, Stephens reaffirmed an “overweight” rating and set a $26.00 price target on shares of Privia Health Group in a research report on Thursday, January 2nd. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Privia Health Group currently has a consensus rating of “Buy” and a consensus price target of $26.67.

Privia Health Group Stock Performance

Privia Health Group stock opened at $23.34 on Monday. The stock has a market capitalization of $2.81 billion, a P/E ratio of 233.42, a price-to-earnings-growth ratio of 3.47 and a beta of 0.85. Privia Health Group, Inc. has a 52 week low of $15.92 and a 52 week high of $26.04. The stock has a fifty day moving average of $23.65 and a 200-day moving average of $21.05.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.